[HTML][HTML] Head and neck squamous cell carcinoma
DE Johnson, B Burtness, CR Leemans… - Nature reviews Disease …, 2020 - nature.com
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity,
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …
pharynx and larynx and are known collectively as head and neck squamous cell carcinoma …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology
MH Shah, WS Goldner, AB Benson… - Journal of the National …, 2021 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
[HTML][HTML] Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
[HTML][HTML] Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion
D Chakravarty, A Johnson, J Sklar… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE An ASCO provisional clinical opinion offers timely clinical direction to ASCO's
membership following publication or presentation of potentially practice-changing data from …
membership following publication or presentation of potentially practice-changing data from …
[HTML][HTML] Genomic–transcriptomic evolution in lung cancer and metastasis
Intratumour heterogeneity (ITH) fuels lung cancer evolution, which leads to immune evasion
and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we …
and resistance to therapy. Here, using paired whole-exome and RNA sequencing data, we …
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
[HTML][HTML] FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients
Y Wang, Z Tong, W Zhang, W Zhang, A Buzdin… - Frontiers in …, 2021 - frontiersin.org
A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …